Antimalarial Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

The Antimalarial Drugs Market was valued at USD 554.20 Million in 2024, and is expected to reach USD 711.04 Million by 2030, rising at a CAGR of 4.44%. With malaria remaining prevalent in regions like sub-Saharan Africa and parts of Asia, demand for effective treatments remains robust. Artemisinin-based combination therapies (ACTs) continue to lead the market due to their efficacy and established role in standard treatment protocols. The market is being further driven by increased investment in research and development aimed at addressing the rise in drug-resistant malaria strains. Innovations such as triple combination therapies, long-acting injectables, and improved formulations for children are being pursued to enhance effectiveness and adherence. While advancements continue, the market faces persistent challenges from evolving resistance patterns, highlighting the need for ongoing development of novel treatment approaches.

Key Market Drivers

Growth in Healthcare Industry

The sustained expansion of the global healthcare industry - projected to surpass USD 4 trillion annually - is significantly bolstering the antimalarial drugs market. Pharmaceuticals and biotechnology contribute nearly USD 850 billion, supported by diagnostics and medical technology. In malaria-endemic regions such as Africa, Asia, and Latin America, increased public and private investment in healthcare infrastructure has enhanced access to diagnostics and treatments. This improved accessibility enables timely intervention, allowing for broader administration of antimalarial drugs and supporting continuous market growth.

Key Market Challenges

Inconsistency in Drug Supply

Supply inconsistency remains a major hurdle in the global antimalarial drugs market, especially in regions where malaria is most prevalent. Despite advancements in drug development and distribution frameworks, many affected areas still experience irregular access to essential medications. This issue is most acute in remote or low-income regions with fragile healthcare infrastructure. Key contributing factors include limited manufacturing capacity, inefficient procurement systems, and logistical obstacles that lead to delayed or insufficient supply. Seasonal fluctuations in malaria cases - often linked to monsoon or rainy seasons - further strain these underprepared supply chains. Inadequate inventory control and fragmented distribution networks can result in stockouts at critical points of care, ultimately disrupting treatment and increasing health risks.

Key Market Trends

Increased Focus on Herbal and Plant-Based Therapies

There is a growing trend toward the development and adoption of herbal and plant-based therapies in the antimalarial drugs market. Plant-derived compounds such as quinine, quinidine, and artemisinin remain pivotal in the fight against malaria. This shift is largely influenced by rising interest in natural and traditional treatments, particularly in regions where indigenous medicine is widely practiced. Concerns regarding side effects of synthetic drugs and the emergence of resistant malaria strains have prompted researchers and pharmaceutical firms to explore botanical alternatives. Artemisinin - extracted from sweet wormwood - serves as a cornerstone of ACTs and exemplifies the clinical success of plant-based remedies. Ongoing exploration of other medicinal plants, including neem and cinchona bark, continues to expand the pipeline of potential antimalarial agents derived from natural sources.

Key Market Players

• Cipla Ltd
• GlaxoSmithKline Plc
• Ipca Laboratories Ltd.
• Merck & Co., Inc
• Novartis AG
• Zydus Cadila
• Sun Pharmaceutical Industries Ltd.
• Strides Pharma Science Limited
• Glenmark Pharmaceuticals Ltd.
• Lincoln Pharmaceuticals Ltd.

Report Scope

In this report, the Global Antimalarial Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antimalarial Drugs Market, By Drug Type:

• Quinine
• Chloroquine
• Proguanil
• Amodiaquine
• Mefloquine
• Hydroxychloroquine
• Pyrimethamine
• Others

Antimalarial Drugs Market, By Malaria Type:

• Plasmodium Falciparum
• Plasmodium Malariae
• Plasmodium Vivax
• Plasmodium Ovale
• Plasmodium Knowlesi

Antimalarial Drugs Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antimalarial Drugs Market.

Available Customizations

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.